Medicare 'Coverage With Evidence' May Rise With FDA Postmarket Emphasis
This article was originally published in The Gray Sheet
As FDA touts plans to shift clinical data requirements when possible to the postmarket phase, a top CMS official highlights the importance of the Medicare coverage with evidence development policy.
You may also be interested in...
Industry stakeholders listed their priorities to improve the medical regulatory process and research during a second hearing at the Senate Health, Education, Labor and Pensions Committee which is working on its own version of the House's 21st Century Cures bill.
A planning board created to develop a framework for a new U.S. medical device surveillance system has proposed a seven year plan on how to get the system up and running, which will include creating incentive systems for stakeholders as well as reducing the burden of recording and managing device data.
CMS issued its final guidance on the coverage-with-evidence-development program, two years following a draft. It is explicit that local Medicare contractors can employ CED in setting coverage policies in their jurisdictions, but it is not clear that the language will encourage significant use at the local level. The guidance also revises its approach on ending CED policies compared to what was stated in the 2012 draft guidance.